Why did VTVT's EPS remain flat in Q4 2024?

The EPS of VTVT remained flat in Q4 2024 due to a combination of factors: 1. **Financial Performance**: VTVT reported a quarterly adjusted loss of 55 cents per share for the quarter ended December 31, 2024. This indicates that the company has continued to operate at a loss, which could be a contributing factor to the flat EPS. 2. **Revenue and Profitability**: The company's revenue for the quarter was $17.00 million. While this is a positive indicator of the company's ability to generate income, the focus on revenue alone does not necessarily impact the EPS, which is a measure of profitability. The fact that VTVT is not profitable over the last twelve months and suffers from weak gross profit margins suggests that the company's expenses are outweighing its revenues, leading to a flat EPS. 3. **Insider Trading Activity**: On November 18, 2024, Paul Sekhri, President, Chief Executive Officer, and Executive Chairperson of vTv Therapeutics Inc, purchased 5,000 shares of the company. Insider buying can sometimes be a bullish signal, indicating confidence in the company's future prospects. However, it does not directly impact the EPS, which is a result of the company's financial performance. In conclusion, the flat EPS of VTVT in Q4 2024 can be attributed to the company's continued financial losses despite some positive revenue indicators. The lack of profitability and weak gross profit margins are the primary factors contributing to the flat EPS.